S-OA-K Oral Abstracts - Session K - Histocompatibility & Clinical Cellular Therapy

Track: BMT Tandem "Scientific" Meeting
Saturday, February 14, 2015: 4:45 PM-6:45 PM
Seaport Ballroom DE (Manchester Grand Hyatt)
Chairs:
Marcelo Fernandez-Vina, PhD and Yoshihisa Kodera, MD, PhD

Disclosures:
M. Fernandez-Vina, Nothing To Disclose

Y. Kodera, Nothing To Disclose

49
Impact of High-Resolution Typing for HLA-a, -B, -C and -DRB1 on Single-Unit Cord Blood Transplantation in Pediatric Patients
Amy E Armstrong, MD, Ann & Robert H. Lurie Children's Hospital of Chicago; Borko Jovanovic, MS, PhD, Northwestern University Feinberg School of Medicine; Alfred Rademaker, Ph.D, Northwestern University Feinberg School of Medicine; Eileen Smyth, Ann & Robert H. Lurie Children's Hospital of Chicago; Sonali Chaudhury, MD, Ann & Robert H. Lurie Children's Hospital of Chicago

50
Developing a Haploidentical Transplant Program: An Indian Experience
Sarita Jaiswal, MD, MANASHI CHAKRABARTI FOUNDATION; Kanika Sharma, MD, DHARAMSHILA HOSPITAL AND RESEARCH CENTRE; Suparno Chakrabarti, MD, FRCPATH, MANASHI CHAKRABARTI FOUNDATION

51
Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Comprehensive Meta-Analysis
Natasha Kekre, MD, FRCPC, Dana-Farber Cancer Institute; Kimberley Mak, MD, Harvard Radiation Oncology Program; Konrad Stopsack, Harvard School of Public Health; Kazusa Ishii, MD, MPH, National Institutes of Health; Moritz Binder, Harvard School of Public Health; Elsa Brånvall, Karolinska University Hospital; Corey S. Cutler, MD, Dana-Farber Cancer Institute, Harvard Medical School

52
Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation
Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center; Brent L. Wood, MD, University of Washington; Colleen Delaney, MD, MSc, Fred Hutchinson Cancer Research Center

53
Mismatched Unrelated Donor Allo-SCT for AML after Reduced Intensity or Ablative Conditioning Regimen- a Report from the Acute Leukemia Working Party of the EBMT
Bipin N. Savani, MD, Vanderbilt University Medical Center; Myriam Labopin, MD, EBMT Paris study office / CEREST-TC; Emmanuelle Polge, Université Pierre et Marie Curie; Nicolaus Kröger, Professor, University Medical Center Hamburg; Jurgen Finke, MD, Freiburg University Medical Center; Gerhard Ehninger, Universitaetsklinikum Dresden; Dietger Niederwieser, MD, University of Leipzig; Slawomira Kyrcz-Krzemien, MD, Silesian Medical Academy; Rainer Schwerdtfeger, MD, PhD, DKD - Wiesbaden; Donald W. Bunjes, MD, University of Ulm; Bertrum Glass, MD, Asklepios Klinik St. Georg - Department of Haematology; Gerard Socié, MD, PhD, Hospital Saint Louis; Per T. Ljungman, MD, PhD, Karolinska University Hospital; Mohamad Mohty, MD, PhD, Department of Haematology, Saint Antoine Hospital; Arnon Nagler, MD, The Chaim Sheba Medical Center, Tel-Hashomer, Division of Hematology and Bone Marrow Transplantation

32
In Vivo Expansion of NK Cells Stimulated with PM21 Particles Under Ultralow IL-2
Jeremiah L Oyer, University of Central Florida; Veethika Pandey, University of Central Florida; Dominic A Colosimo, University of Central Florida; Robert Y Igarashi, PhD, University of Central Florida; Ahmed Zakari, MD, Florida Hospita; Melhem Solh, MD, Florida Hospital Cancer Institute; Deborah A Altomare, PhD, University of Central Florida; Alicja J. Copik, PhD, University of Central Florida

33
CMVpp65-Specific T Cells Generated from Naïve T Cell Populations Recognize Atypical but Not Canonical Epitopes and May be Protective in Vivo
Patrick J Hanley, PhD, Children's National Medical Center; Jan Melenhorst, BS, PhD, National Institutes of Health, National Heart, Lung, and Blood Institute; Sarah Nikiforow, MD PhD, Dana-Farber Cancer Institute, Harvard Medical School; Phillip Scheinberg, MD, Hospital Beneficência Portuguesa de São Paulo; Russell Cruz, MD, PhD, Children's National Medical Center; Robert A. Krance, MD, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital; Kathryn Leung, MD, Baylor College of Medicine, Texas Children's Hospital; Caridad Martinez, MD, Baylor College of Medicine, Texas Children's Hospital; Helen E. Heslop, MD, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital; Cliona M. Rooney, PhD, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital; A. John Barrett, MD, National Heart, Lung, and Blood Institute, NIH; Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center; Catherine M. Bollard, MD, Children's National Medical Center

108
IGF1R- and ROR1-Specific Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas
Haein Park, PhD, New York Medical College; Xin Huang, MD, New York Medical College; Joseph Greene, BA, Masonic Cancer Center, University of Minnesota; James Pao, BA, New York Medical College; Erin Mulvey, BA, New York Medical College; Sophia X Zhou, Masonic Cancer Center, University of Minnesota; Deepali Sachdev, PhD, Masonic Cancer Center, University of Minnesota; Douglas Yee, MD, Masonic Cancer Center, University of Minnesota; Christoph Rader, PhD, The Scripps Research Institute; Catherine M Albert, MD, Johns Hopkins Medical School; Carl Hamby, PhD, New York Medical College; David Loeb, MD, PhD, Johns Hopkins Hospital; Mitchell S. Cairo, MD, New York Medical College; Xianzheng Zhou, PhD, New York Medical College